Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells - A Randomized, Double-Blind, Placebo-Controlled Study - The STAR-II Trial

NCT05148598 is registered in ClinicalTrials.gov with Paracrine, INC. as lead sponsor.

NCT NCT05148598
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05148598 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells - A Randomized, Double-Blind, Placebo-Controlled Study - The STAR-II Trial
Lead sponsor
Paracrine, INC.
Phase
Phase 3
Overall status
Unknown status
Start date
February 28, 2023
Completion date
December 30, 2025
Enrollment
174 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

scleroderma, diffuse